BiotechTube

SHR- A1811

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gynaecological Malignancies

Conditions

Gynaecological Malignancies

Trial Timeline

Jul 10, 2023 → Jun 15, 2026

NCT ID
NCT05896020

About SHR- A1811

SHR- A1811 is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Gynaecological Malignancies. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05896020. Target conditions include Gynaecological Malignancies.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05896020Phase 2Recruiting

Competing Products

1 competing product in Gynaecological Malignancies

See all competitors
ProductCompanyStageHype Score
Ceralasertib + Olaparib + DurvalumabAstraZenecaPhase 2
52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85